Jian Zhou

14.5k total citations · 9 hit papers
225 papers, 6.6k citations indexed

About

Jian Zhou is a scholar working on Oncology, Surgery and Hepatology. According to data from OpenAlex, Jian Zhou has authored 225 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 70 papers in Surgery and 62 papers in Hepatology. Recurrent topics in Jian Zhou's work include Hepatocellular Carcinoma Treatment and Prognosis (53 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (38 papers) and Cancer Immunotherapy and Biomarkers (23 papers). Jian Zhou is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (53 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (38 papers) and Cancer Immunotherapy and Biomarkers (23 papers). Jian Zhou collaborates with scholars based in China, Ethiopia and United States. Jian Zhou's co-authors include Jia Fan, Qiang Gao, Xin‐Rong Yang, Ao Huang, Wen Yuan Chung, Ashley R. Dennison, Diyang Xie, Zhenggang Ren, Yongyong Shi and Shuang‐Jian Qiu and has published in prestigious journals such as Angewandte Chemie International Edition, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jian Zhou

205 papers receiving 6.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

2009 663 citations Qiang Gao, Xiaoying Wang et al. Clinical Cancer Research profile →
Targeted therapy for hepatocellular carcinoma

2020 508 citations Xin‐Rong Yang, Jian Zhou et al. profile →
Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma

2023 354 citations Jian Zhou, Jia Fan et al. profile →
2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights

2020 310 citations Jian Zhou, Jia Fan et al. profile →
CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor

2023 209 citations Zheng Tang, Run Huang et al. profile →
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

2020 194 citations Jian Zhou et al. Liver Cancer profile →
Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations

2021 159 citations Xiao‐Dong Zhu, Cheng Huang et al. Liver Cancer profile →
PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma

2022 114 citations Xiaoyong Huang, Zheng Tang et al. profile →
A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights

2023 84 citations Jian Zhou, Jia Fan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jian Zhou China	39	2.5k	2.0k	1.8k	1.8k	1.2k	225	6.6k
Shuang–Jian Qiu China	48	2.7k 1.1×	3.6k 1.8×	2.0k 1.1×	2.1k 1.2×	990 0.8×	174	8.6k
Li‐Tzong Chen Taiwan	41	2.4k 0.9×	2.6k 1.3×	1.2k 0.7×	1.2k 0.7×	600 0.5×	296	7.3k
Moritz Koch Germany	46	2.2k 0.9×	4.6k 2.2×	2.1k 1.2×	943 0.5×	1.2k 1.0×	98	7.8k
Jesper B. Andersen Denmark	41	3.3k 1.3×	1.5k 0.7×	2.4k 1.3×	908 0.5×	491 0.4×	113	5.8k
Ahmed O. Kaseb United States	42	1.8k 0.7×	2.9k 1.4×	1.5k 0.8×	3.7k 2.1×	680 0.6×	263	8.1k
Zhi Dai China	38	2.7k 1.1×	1.7k 0.8×	1.9k 1.1×	677 0.4×	1.3k 1.1×	97	5.4k
Bo Zhai China	37	3.1k 1.2×	1.3k 0.6×	1.4k 0.7×	889 0.5×	503 0.4×	152	5.4k
Ronnie T.P. Poon Hong Kong	42	1.6k 0.6×	1.5k 0.7×	1.3k 0.7×	3.4k 1.9×	535 0.5×	89	6.1k
Qiongzhu Dong China	49	4.5k 1.8×	1.8k 0.9×	3.6k 2.0×	701 0.4×	1.1k 0.9×	131	7.4k
Stephanie Ma Hong Kong	47	5.0k 2.0×	3.9k 1.9×	3.0k 1.6×	1.4k 0.8×	940 0.8×	125	8.8k

Countries citing papers authored by Jian Zhou

Since Specialization

Citations

This map shows the geographic impact of Jian Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jian Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jian Zhou more than expected).

Fields of papers citing papers by Jian Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jian Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jian Zhou. The network helps show where Jian Zhou may publish in the future.

Co-authorship network of co-authors of Jian Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Jian Zhou. A scholar is included among the top collaborators of Jian Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jian Zhou. Jian Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

He, Yifeng, Xiaowu Huang, Xiaoyong Huang, et al.. (2025). Graft PD-L1 as a predictive marker for rejection in PD-1 inhibitor therapy for recurrent liver tumors after transplant: A prospective pilot trial. Liver Transplantation. 32(2). 135–143.

Su, Zhendong, et al.. (2025). Cigarette defect detection based on independent feature extraction constraints. Electronics Letters. 61(1).

Wang, Han, Fangming Liu, Xiaoling Wu, et al.. (2024). Cancer-associated fibroblasts contributed to hepatocellular carcinoma recurrence and metastasis via CD36-mediated fatty-acid metabolic reprogramming. Experimental Cell Research. 435(2). 113947–113947. 23 indexed citations

Sun, Hui‐Chuan, Xiao‐Dong Zhu, Ziyi Wang, et al.. (2024). Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis. SHILAP Revista de lepidopterología. 3(1). e000578–e000578. 1 indexed citations

Xu, Bin, Ziyi Wang, He Tian, et al.. (2024). Depth of Radiographic Response as an Independent Prognostic Factor for Patients with Initially Unresectable Hepatocellular Carcinoma Receiving Hepatectomy following Targeted Therapy plus Immunotherapy. Liver Cancer. 14(2). 1–16. 1 indexed citations

Li, Yueshuo, Longlong Xie, Feng Shi, et al.. (2024). CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma. Cell Death and Disease. 15(1). 95–95. 7 indexed citations

Sun, Hui‐Chuan, Ying‐Hao Shen, Xiao‐Dong Zhu, et al.. (2023). The development and prospects of liver surgery. SHILAP Revista de lepidopterología. 2(1). 100009–100009.

Gao, Jun, Yuan Fang, Jiafeng Chen, et al.. (2023). Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy. Oncogene. 42(33). 2507–2520. 28 indexed citations

Cheng, Jie, Chenguang Wang, Chunyang Zhao, et al.. (2023). A Randomized, Single‐Dose, Parallel‐Controlled Phase 1 Clinical Comparison of an Omalizumab Biosimilar Candidate with Reference Omalizumab in Healthy Chinese Male Volunteers. Clinical Pharmacology in Drug Development. 13(4). 349–359.

10.

Li, Jia, Zhiqiang Hu, Songyang Yu, et al.. (2022). CircRPN2 Inhibits Aerobic Glycolysis and Metastasis in Hepatocellular Carcinoma. Cancer Research. 82(6). 1055–1069. 100 indexed citations

11.

Jin, Anli, Chunyan Zhang, Wenjing Zheng, et al.. (2022). CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis. Clinical and Translational Medicine. 12(4). e794–e794. 26 indexed citations

12.

Xiao, Nan, Xiao‐Long Li, Xiao‐Dong Zhu, et al.. (2021). Increase of Portal Vein Pressure Gradient After Hepatectomy Predicts Post-operative Liver Dysfunction. Surgical Innovation. 29(2). 145–153.

13.

Song, Fei, Bo Hu, Jianwen Cheng, et al.. (2020). Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death and Disease. 11(7). 573–573. 87 indexed citations

14.

Zhou, Jian, et al.. (2020). Diagnosis Value of Combined Detection of Serum SF, CEA and CRP in Non-Small Cell Lung Cancer. SHILAP Revista de lepidopterología. 3 indexed citations

15.

Zhang, Wei, Yang Li, Ke Shen, et al.. (2020). Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma. BMC Cancer. 20(1). 714–714. 12 indexed citations

16.

He, Jia, Qiaozhu Zuo, Bo Hu, et al.. (2019). A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA. Cancer Letters. 450. 98–109. 98 indexed citations

17.

Zhou, Jian, et al.. (2017). Kidney transplantation from donors with rhabdomyolysis and acute renal failure. Clinical Transplantation. 31(8). 4 indexed citations

18.

Huang, Cheng Zhi, Guangyu Ding, Chengyu Gu, et al.. (2012). Decreased Selenium-Binding Protein 1 Enhances Glutathione Peroxidase 1 Activity and Downregulates HIF-1α to Promote Hepatocellular Carcinoma Invasiveness. Clinical Cancer Research. 18(11). 3042–3053. 83 indexed citations

19.

Gao, Qiang, Xiaoying Wang, Shuang‐Jian Qiu, et al.. (2009). Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma. Clinical Cancer Research. 15(3). 971–979. 663 indexed citations breakdown →

20.

Zhou, Jian. (2000). Study on inhibition of the growth and metastasis of LCID20 hepatocellular carcinoma by Capecitabine. Zhonghua shiyan waike zazhi. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact